Murine chronic-relapsing experimental allergic encephalomyelitis (R-EAE) follows a progressive or relapsing-remitting course of paralysis. R-EAE is characterized histologically by perivascular mononuclear cell-rich infiltrates of the white matter of the central nervous system (CNS) and areas of acute and chronic demyelination. The well-understood genetics of the murine host and the similarities in both clinical course and histopathology of murine R-EAE and the human demyelinating disease multiple sclerosis (MS) make it an ideal animal model for the study of immunoregulatory aspects of MS. We propose to examine the neuroantigen specificity of T cell-mediated immune (CMI) throughout the clinical course of R-EAE and to examine the conditions and mechanisms by which the induction and/or expression of R-EAE can be modified following monoclonal antibody immunotherapy and following the induction of neuroantigen-specific immunological tolerance. The relative contribution of CMI responses to various components of the myelin membrane (e.g. myelin basic protein (MBP), proteolipid protein (PLP), galactocerebroside (GC), and myelin-associated glycoprotein (MAG)) to both the initial clinical signs of disease and to relapsing episodes of R-EAE induced by priming with whole spinal cord homogenate in complete Freund's adjuvant will be studied. The mechanisms by which disease induction is inhibited by monoclonal antibodies directed against MHC class II-restricted T cells (helper/delayed-type hypersensitivity) and exacerbated by monoclonal antibodies directed against MHC class I-restricted T cells (cytotoxic/suppressor) will also be investigated. The major effort will be devoted to expanding our preliminary studies dealing with disease modulation via the induction of neuroantigen- specific immunological tolerance. The relative effects of antigen-specific immune tolerance and suppressor T cell induction on clinical and histopathological disease parameters and neuroantigen-specific CMI responses will be assessed in mice tolerized via the iv injection on neuroantigen-coupled syngeneic splenocytes. These studies should lead to a better understanding of the fine specificity, immunopathologic role, and immunoregulation of T cell-mediated immune responses to various neuroantigens in murine EAE which may be applicable to the understanding and treatment of human MS.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
5R01NS026543-05
Application #
3412476
Study Section
Pathology A Study Section (PTHA)
Project Start
1988-07-01
Project End
1993-06-30
Budget Start
1992-07-01
Budget End
1993-06-30
Support Year
5
Fiscal Year
1992
Total Cost
Indirect Cost
Name
Northwestern University at Chicago
Department
Type
Schools of Dentistry
DUNS #
005436803
City
Chicago
State
IL
Country
United States
Zip Code
60611
Prasad, Suchitra; Neef, Tobias; Xu, Dan et al. (2018) Tolerogenic Ag-PLG nanoparticles induce tregs to suppress activated diabetogenic CD4 and CD8 T cells. J Autoimmun 89:112-124
Podojil, Joseph R; Miller, Stephen D (2017) Potential targeting of B7-H4 for the treatment of cancer. Immunol Rev 276:40-51
Kuo, Robert; Saito, Eiji; Miller, Stephen D et al. (2017) Peptide-Conjugated Nanoparticles Reduce Positive Co-stimulatory Expression and T Cell Activity to Induce Tolerance. Mol Ther 25:1676-1685
Pearson, Ryan M; Casey, Liam M; Hughes, Kevin R et al. (2017) In vivo reprogramming of immune cells: Technologies for induction of antigen-specific tolerance. Adv Drug Deliv Rev 114:240-255
Kang, Hee Kap; Wang, Shusen; Dangi, Anil et al. (2017) Differential Role of B Cells and IL-17 Versus IFN-? During Early and Late Rejection of Pig Islet Xenografts in Mice. Transplantation 101:1801-1810
Jeong, Su Ji; Cooper, John G; Ifergan, Igal et al. (2017) Intravenous immune-modifying nanoparticles as a therapy for spinal cord injury in mice. Neurobiol Dis 108:73-82
Edwards, Rebecca G; Kopp, Sarah J; Ifergan, Igal et al. (2017) Murine Corneal Inflammation and Nerve Damage After Infection With HSV-1 Are Promoted by HVEM and Ameliorated by Immune-Modifying Nanoparticle Therapy. Invest Ophthalmol Vis Sci 58:282-291
McCarthy, Derrick P; Yap, Jonathan Woon-Teck; Harp, Christopher T et al. (2017) An antigen-encapsulating nanoparticle platform for TH1/17 immune tolerance therapy. Nanomedicine 13:191-200
Neef, Tobias; Miller, Stephen D (2017) Tolerogenic Nanoparticles to Treat Islet Autoimmunity. Curr Diab Rep 17:84
Pearson, Ryan M; Casey, Liam M; Hughes, Kevin R et al. (2017) Controlled Delivery of Single or Multiple Antigens in Tolerogenic Nanoparticles Using Peptide-Polymer Bioconjugates. Mol Ther 25:1655-1664

Showing the most recent 10 out of 150 publications